Profile of:

Seung Cheol Shim

Full name: Seung Cheol Shim

Current country: South Korea

Membership level: Full

Type of membership: Member

Number of publications: 11

STAT3 Phosphorylation Inhibition for Treating Inflammation and New Bone Formation in Ankylosing Spondylitis. (2020)

Switching to biosimilars in the treatment of rheumatic diseases (2018)

Expression of activation-induced cytidine deaminase splicing variants in patients with ankylosing spondylitis (2017)

Developing a Risk-scoring Model for Ankylosing Spondylitis Based on a Combination of HLA-B27, Single-nucleotide Polymorphism, and Copy Number Variant Markers. (2016)

Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research. (2016)

An HLA-C amino-acid variant in addition to HLA-B*27 confers risk for ankylosing spondylitis in the Korean population (2015)

ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients (2015)

Bone morphogenetic protein 6 polymorphisms are associated with radiographic progression in ankylosing spondylitis (2014)

Genome-wide copy number variation analysis identifies deletion variants associated with ankylosing spondylitis (2014)

Restoration of overexpressed variable heavy chain 2 transcripts with tumor necrosis factor inhibitors in ankylosing spondylitis (2014)

Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci (2013)